137 related articles for article (PubMed ID: 34030114)
1. Cantilever-centric mechanism of cooperative non-active site mutations in HIV protease: Implications for flap dynamics.
Sherry D; Worth R; Ismail ZS; Sayed Y
J Mol Graph Model; 2021 Jul; 106():107931. PubMed ID: 34030114
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics and ligand docking of a hinge region variant of South African HIV-1 subtype C protease.
Zondagh J; Balakrishnan V; Achilonu I; Dirr HW; Sayed Y
J Mol Graph Model; 2018 Jun; 82():1-11. PubMed ID: 29625416
[TBL] [Abstract][Full Text] [Related]
3. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
4. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
C S V; Tamizhselvi R; Munusami P
J Biomol Struct Dyn; 2019 Jul; 37(10):2608-2626. PubMed ID: 30051758
[TBL] [Abstract][Full Text] [Related]
5. Structural Studies of a Rationally Selected Multi-Drug Resistant HIV-1 Protease Reveal Synergistic Effect of Distal Mutations on Flap Dynamics.
Agniswamy J; Louis JM; Roche J; Harrison RW; Weber IT
PLoS One; 2016; 11(12):e0168616. PubMed ID: 27992544
[TBL] [Abstract][Full Text] [Related]
6. Flap-site Fragment Restores Back Wild-type Behaviour in Resistant Form of HIV Protease.
Luchi A; Angelina E; Bogado L; Forli S; Olson A; Peruchena N
Mol Inform; 2018 Dec; 37(12):e1800053. PubMed ID: 30051611
[TBL] [Abstract][Full Text] [Related]
7. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
8. Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations.
Kneller DW; Agniswamy J; Harrison RW; Weber IT
FEBS J; 2020 Aug; 287(15):3235-3254. PubMed ID: 31920003
[TBL] [Abstract][Full Text] [Related]
9. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
Seibold SA; Cukier RI
Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
[TBL] [Abstract][Full Text] [Related]
10. The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints.
Ahmed SM; Maguire GE; Kruger HG; Govender T
Chem Biol Drug Des; 2014 Apr; 83(4):472-81. PubMed ID: 24267738
[TBL] [Abstract][Full Text] [Related]
11. Multiple Molecular Dynamics Simulations and Free-Energy Predictions Uncover the Susceptibility of Variants of HIV-1 Protease against Inhibitors Darunavir and KNI-1657.
Wang R; Zheng Q
Langmuir; 2021 Dec; 37(49):14407-14418. PubMed ID: 34851643
[TBL] [Abstract][Full Text] [Related]
12. Drug Resistance Mechanism of M46I-Mutation-Induced Saquinavir Resistance in HIV-1 Protease Using Molecular Dynamics Simulation and Binding Energy Calculation.
Rana N; Singh AK; Shuaib M; Gupta S; Habiballah MM; Alkhanani MF; Haque S; Reshi MS; Kumar S
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458427
[TBL] [Abstract][Full Text] [Related]
13. Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis.
Karnati KR; Wang Y
J Mol Graph Model; 2019 Nov; 92():112-122. PubMed ID: 31351319
[TBL] [Abstract][Full Text] [Related]
14. Natural Polymorphisms D60E and I62V Stabilize a Closed Conformation in HIV-1 Protease in the Absence of an Inhibitor or Substrate.
Tran TT; Fanucci GE
Viruses; 2024 Feb; 16(2):. PubMed ID: 38400012
[TBL] [Abstract][Full Text] [Related]
15. Exploring the flap dynamics of the South African HIV subtype C protease in presence of FDA-approved inhibitors: MD study.
Maphumulo SI; Halder AK; Govender T; Maseko S; Maguire GEM; Honarparvar B; Kruger HG
Chem Biol Drug Des; 2018 Nov; 92(5):1899-1913. PubMed ID: 30003668
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.
Agniswamy J; Shen CH; Aniana A; Sayer JM; Louis JM; Weber IT
Biochemistry; 2012 Apr; 51(13):2819-28. PubMed ID: 22404139
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
Naicker P; Achilonu I; Fanucchi S; Fernandes M; Ibrahim MA; Dirr HW; Soliman ME; Sayed Y
J Biomol Struct Dyn; 2013 Dec; 31(12):1370-80. PubMed ID: 23140382
[TBL] [Abstract][Full Text] [Related]
18. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
[TBL] [Abstract][Full Text] [Related]
19. Binding of single walled carbon nanotube to WT and mutant HIV-1 proteases: analysis of flap dynamics and binding mechanism.
Meher BR; Wang Y
J Mol Graph Model; 2012 Sep; 38():430-45. PubMed ID: 23142620
[TBL] [Abstract][Full Text] [Related]
20. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.
Meher BR; Wang Y
J Mol Graph Model; 2015 Mar; 56():60-73. PubMed ID: 25562662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
